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Abstract 
Introduction: There is limited data in the literature about brucellosis related to an intracellular pathogen and anti-tumor necrosis factor alpha 
(anti-TNFα) medication. The aim of this study was to evaluate acute Brucella infections in mice receiving anti-TNFα drug treatment.  
Methodology: Anti-TNFα drugs were injected in mice on the first and fifth days of the study, after which the mice were infected with B. 
melitensis M16 strain. Mice were sacrificed on the fourteenth day after infection. Bacterial loads in the liver and spleen were defined, and 
histopathological changes were evaluated.  
Results: Neither the liver nor the spleen showed an increased bacterial load in all anti-TNFα drug groups when compared to a non-treated, 
infected group. The most significant histopathological findings were neutrophil infiltrations in the red pulp of the spleen and apoptotic cells 
with hepatocellular pleomorphism in the liver. There was no significant difference among the groups in terms of previously reported 
histopathological findings, such as extramedullary hematopoiesis and granuloma formation.  
Conclusions: There were no differences in hepatic and splenic bacterial load and granuloma formation, which indicate worsening of the acute 
Brucella infection in mice; in other words, anti-TNFα treatment did not exacerbate the acute Brucella spp. infection in mice. 
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Introduction 
Anti-tumor necrosis factor alpha (TNFα) drugs are 
widely used for rheumatoid arthritis, ankylosing 
spondylitis, inflammatory bowel disease, psoriasis, 
psoriatic arthritis, and juvenile chronic arthritis. 
However, anti-TNFα drug therapy is associated with 
increased risk of infection, including non-typhoidal 
salmonellosis, listeriosis, pneumocystosis, and other 
fungal or viral infections, but Mycobacterium 
tuberculosis infection incidence is especially increased 
in patients who are treated with these drugs [1,2]. 
Brucellosis is still endemic in some parts of the 
world, and approximately 500,000 new cases are 
reported annually [3]. Brucella spp. are intracellular 
bacteria that release cytokines such as IFN-gamma, 
IL-2, and TNFα. Activated macrophages and dendritic 
cells are required for the immune response against 
Brucella infection [4-6]. TNFα has a critical role in 
macrophage activation, apoptosis, proinflammatory 
cytokine release, and granuloma formation. It is 
required for bactericidal effects and clearance of 
Brucella infection [7-9]. Although it was reported that 
TNFα was not secreted by mouse macrophages 
infected with B. melitensis [10], TNFα gene 
expression and induction was demonstrated in in vitro 
and in vivo studies conducted with mice macrophage, 
splenocyte, and dendritic cells [11-13]. Additionally, 
the increased TNFα serum level was shown with B. 
abortus infection, but not with B. melitensis [14]. 
Although brucellosis is an endemic disease and there 
is a widespread use of anti-TNFα drugs for different 
indications, reactivation of brucellosis can be expected 
more frequently. However, there are only three case 
reports about brucellosis reactivation due to anti-TNFα 
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drug therapy [15-17]. In this study, we aimed to 
investigate the responses to acute Brucella infection in 
mice receiving adalimumab (ADA), etanercept (ETN), 
and infliximab (IFX) by evaluating the splenic and 
hepatic bacterial loads as well as histopathological 
findings. 
 
Methodology 
Bacteria 
This study used a standard smooth strain of B. 
melitensis provided by the Pendik Veterinary Control 
and Research Institute in Istanbul, Turkey. 
Lyophilized bacteria were suspended in phosphate 
buffered saline (PBS) and cultured on horse blood agar 
(HBA) plates for three days at 37°C with 5% CO2. 
 
Animals, infections, and anti-TNFα drugs  
The study was carried out according to the ethical 
guidelines (no. 2011.035) of the Medical Ethics 
Committee of Pamukkale University, Denizli, Turkey. 
A total of 56 BALB/c mice between eight and ten 
weeks of age, weighing between 30 and 40 grams, 
were included in the study. During the experiment 
period, six mice were excluded from the analysis due 
to preterm death. The control groups (CG) (non-
infected-CG, n = 6; infected-CG, n = 7) and following 
test groups were examined: ADA (adalimumab, n = 
6); ADA + B. melitensis (adalimumab with acute B. 
melitensis infection, n = 6); ETN (etanercept, n = 6); 
ETN + B.melitensis (etanercept with acute B. 
melitensis infection, n = 7); IFX (infliximab, n = 6); 
and IFX + B. melitensis (infliximab with acute B. 
melitensis infection, n = 6).  
On days 1 and 5 of the experiment period, drugs 
were administered subcutaneously to the ADA (2 
mg/kg), ETN (0.4 mg/kg), and IFX (10 mg/kg) groups, 
while 100 µL PBS injections were given to the control 
group. The aim of this study was to evaluate acute 
Brucella infection in mice receiving anti-TNFα drug 
treatment, so a pre-infection regime was preferred, and 
the treatment was repeatedly performed as in previous 
studies [18-20]. Test groups were intraperitoneally 
inoculated with 4x10
4
 colony-forming units (cfu) of B. 
melitensis M16 strain on day 5. Optimal doses were 
described by previous studies for virulent Brucella, 
and in this study, the infective dose was administered 
as in some other studies on a B. melitensis model 
[11,13,21]. 
 
Measurement of bacterial load in liver and spleen 
On day 19 (the 14
th
 day of infection), the spleen 
and liver were aseptically removed, weighed, and 
placed in sterile Petri dishes with 10 mL of saline. The 
organs were homogenized for quantitative bacterial 
load by mincing them with two no. 15 scalpels and 
homogenizing by pushing them through the mesh with 
a sterile syringe plunger. Aliquots of 0.1 mL spleen 
and liver homogenate samples were diluted tenfold 
serially in PBS. Next, 100 µL homogenates of each 
dilution were cultured on HBA plates at 37°C with 5% 
CO2 for five days. The quantitative bacterial load of 
each sample was determined by log conversion. 
 
Histopathology  
Tissue samples of the spleen and liver taken from 
each mouse were fixed in 10% buffered formalin 
placed in paraffin blocks, sectioned at 5 µm, and 
stained with haematoxylin and eosin for histological 
evaluation. Two pathologists performed a blinded 
evaluation of histopathological changes in the spleen 
and liver, using the following histopathological 
evaluation criteria: 
 
Spleen 
Granuloma – 0: absent, 1: micro granuloma, 2: 
macro granuloma; extramedullary hematopoiesis – 0: 
absent, 1: mild, 2: moderate, 3: severe; lymphoid 
tissue depletion – 0: absent, 1: mild, 2: moderate, 3: 
severe; neutrophil infiltration in the red pulp – 0: 
absent, 1: present. 
 
Liver 
Granuloma – 0: absent, 1: micro granuloma, 2: 
macro granuloma; extramedullary hematopoiesis – 0: 
absent, 1: mild, 2: moderate, 3: severe; apoptotic cells 
– 0: absent/minimal, 1: present; portal inflammation – 
0: absent, 1: mild, 2: moderate, 3: severe; perivascular 
mononuclear infiltration – 0: absent, 1: present; 
Kuppfer cell hyperplasia – 0: absent, 1: mild, 2: 
moderate, 3: severe; and hepatocellular pleomorphism 
– 0: absent, 1: present. 
 
Statistical analysis  
The statistical analysis was carried out using SPSS 
software version 17. The bacterial load in the spleen 
and liver were analyzed using the Mann-Whitney U 
test (two group comparison) and the Kruskal-Wallis 
test (multi group comparison). The histopathological 
findings of the spleen and liver were analyzed by the 
Chi-square and Kruskal-Wallis tests. Statistical 
significance was set at p < 0.05.  
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Results 
Quantitative spleen bacterial load  
Bacterial growth was observed in spleen tissue 
cultures of all infected mice. The lowest bacteria 
number was in the ETN + B.melitensis group, while 
the highest was in the IFX + B. melitensis group 
(Figure 1). There was no difference in quantitative 
splenic bacterial load between the groups receiving 
infected-CG and anti-TNFα. The IFX + B. melitensis 
group had a higher bacterial load when compared to 
the ETN + B. melitensis and ADA + B. melitensis 
groups (p = 0.010 and p = 0.025, respectively). 
 
Quantitative liver bacterial load  
There was bacterial growth in the majority of 
hepatic tissue cultures except in two mice in the ETN 
+ B. melitensis group. These two subjects were not 
excluded from the analysis, because both 
demonstrated bacterial growth in the spleen and 
histopathological changes in the liver and spleen. 
Bacterial load was lower in the ETN + B. melitensis 
group than in the infected-CG, ADA + B. melitensis, 
and IFX + B. melitensis groups, and there was a 
significant difference between the ETN + B. melitensis 
and infected-CG groups (p = 0.025) (Figure 2). 
 
Spleen histopathology  
Extramedullary hematopoiesis was determined in 
all infected samples, but there was no significant 
difference between the scores of the groups. 
Granuloma formation was detected in 19 samples 
(73%), and there was no significant difference in 
granuloma formation and lymphoid tissue changes 
between the groups (Table 1). Neutrophil infiltration 
in the red pulp was more prominent in the groups that 
were administered anti-TNFα, and there was a 
statistically significant difference between the ADA + 
B. melitensis and infected-CG groups (p = 0.026) 
(Figure 3). 
 
Liver histopathology  
Although granuloma was determined in all 
samples, extramedullary hematopoiesis was detected 
in only 13 samples (50%). There was no significant 
difference in terms of granuloma formation, 
extramedullary hematopoiesis, portal inflammation, 
perivascular mononuclear infiltration, and Kuppfer 
cell hyperplasia between the groups (Table 1). 
Hepatocellular pleomorphism was more prominent in 
the IFX + B. melitensis group than in the infected-CG 
group (p = 0.026) (Figure 4). Additionally, apoptotic 
cells in the IFX + B. melitensis group were more 
distinctive than in the infected-CG, ADA + B. 
melitensis, and ETN + B. melitensis groups (p = 0.026, 
p = 0.046, and p = 0.067, respectively) (Figure 5). 
 
Discussion 
The results of this study revealed that there was no 
significant increase in splenic and hepatic bacterial 
load during acute B. melitensis infection in mice 
resulting from anti-TNFα drug treatment. Previously, 
it was shown that TNFα was required for bacterial 
clearance in a mouse model of brucellosis [7]. 
Furthermore, splenic bacterial load was increased 
during acute Brucella infection in both  TNFα gene 
deficient mice and mice receiving anti-TNFα 
monoclonal antibody [22,23].  
Figure 1. Comparisons of the groups are shown in terms of the 
spleen tissue bacterial load. Values are mean ± standard error 
of mean (SEM)  
*p < 0.05 vs. ADA + B. melitensis, ETN + B. melitensis by Mann-
Whitney U test 
Figure 2. Comparisons of the groups are shown in terms of the 
liver tissue bacterial load. Values are mean ± standard error of 
mean (SEM)  
*p < 0.05 vs. ETN + B. melitensis by the Mann-Whitney U test 
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  Table 1. Histopathological findings of acute Brucella melitensis M16 infection in mice treated with anti tumor necrosis 
factor-alpha drugs 
Organ, pathological findings 
Infected-CG 
(n = 7) 
ADA + B. 
melitensis  
(n = 6) 
ETN + B. 
melitensis  
(n = 7) 
IFX + B. 
melitensis 
(n = 6) 
P 
Spleen      
Granuloma mean grade (SEM) 1.14 (0.34) 1.67 (0.61) 1.14 (0.40) 1.17 (0.30) .257 
Extramedullary hematopoiesis, mean grade 
(SEM) 
0.57 (0.37) 1.17 (0.40) 1.29 (0.47) 2.0 (0.4) .242 
Lymphoid tissue depletion, mean grade 
(SEM) 
1.71 (0.5) 2.17 (0.4) 1.43 (0.2) 2.5 (0.34) .209 
Neutrophil infiltration in the red pulp 
(present/absent) 
3/4 6/0* 5/2 5/1 .122 
Liver      
Granuloma, mean grade (SEM) 2.71 (0.28) 2.33 (0.33) 1.71 (0.36) 2.67 (0.33) .122 
Extramedullary hematopoiesis, mean grade 
(SEM) 
0.57 (0.37) 1.17 (0.40) 1.29 (0.47) 1.17 (0.54) .651 
Apoptotic cells (present/absent) 3/4 3/3 3/4 6/0** .159 
Portal inflammation, mean grade (SEM) 1.43 (0.36) 0.67 (0.33) 1.57 (0.42) 1 (0.36) .369 
Perivascular mononuclear infiltration 
(present/absent) 
4/3 1/5 5/2 2/4 .201 
Kuppfer cell hyperplasia, mean grade 
(SEM) 
1.86 (0.34) 2.0 (0.51) 1.71 (0.36) 2.67 (0.21) .256 
Hepatocellular pleomorphism  
(present/absent) 
3/4 5/1 6/1 6/0*** .078 
SEM: standard error of mean 
*p < 0.05 vs. infected-CG; **p < 0.05 vs. infected-CG and ADA + B. melitensis group; ***p < 0.05 vs. infected-CG 
Figure 3. Neutrophil infiltration in the spleen red pulp: a) infected-CG group; b) ADA + B.  melitensis group; c) ETN + B. melitensis 
group; d) IFX + B. melitensis group (H&E, x400 magnification) 
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Figure 4. Hepatocellular pleomorphism in the liver: a) infected-CG group; b) ADA + B. melitensis group; c) ETN + B. melitensis group; 
d) IFX + B. melitensis group (H&E, x400 magnification) 
Figure 5. Apoptotic cells in the liver: a) infected-CG group; b) ADA + B. melitensis group; c) ETN + B. melitensis group; d) IFX + B. 
melitensis group (H&E, x400 magnification) 
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The reason our findings differed from those of 
previous reports may be the administration of anti-
TNFα drugs used in daily medical practice.  
In the present study, there was no higher bacterial 
load in groups receiving anti-TNFα drugs when 
compared to the control group, but some findings are 
still worthy of note.  
First, hepatic bacterial load was lower in the ETN 
+ B. melitensis group than in the infected-CG group (p 
= 0.025). Previous studies showed that TNFα 
stimulation of the hepatocytes of mice leads to TLR 2 
and TLR 4 up-regulation, whereas TNFα blockage 
leads to their down-regulation [24]. In a recent study, 
it was reported that TLR 2 and 4 did not have a role in 
controlling hepatic infection in a mouse model of B. 
melitensis, and hepatic bacterial clearance started in 
TLR 2 and TLR 4 of knock-out mice after the second 
week of infection [25]. However, in the spleen, it was 
shown that TLR 4, but not TLR 2, was required to 
control Brucella infection [13,25,26]. These data may 
explain the lower hepatic bacterial load in the ETN + 
B. melitensis group as well as the absence of bacterial 
growth in two liver samples. However, TLR 4 is 
required for bacterial clearance in the spleen, and 
therefore splenic bacterial load was unchanged. 
Another factor influencing this result may be related to 
ineffectiveness of etanercept on the events related to 
the p55 receptor, unlike other drugs [27]. 
Second, splenic bacterial loads of the experiment 
groups are shown in Figure 1. In the IFX + B. 
melitensis group, the splenic bacterial load was 
significantly higher than the other two drug groups; 
however, none of the drug groups demonstrated a 
splenic bacterial load different from the control group. 
IFX is a human-mouse chimeric TNFα inhibitor, and it 
exerts its potential effect by binding both to soluble 
TNFα and transmembranal TNFα. Structural and 
pharmacological differences of the drugs may play a 
role in detecting higher bacterial load in the IFX + B. 
melitensis group than the other two drug groups [27]. 
As mentioned earlier, TLR 4 is essential for splenic 
bacterial clearance, and anti-TNFα drugs inhibit the 
expression of TLR 4 and TLR 2. It has been 
demonstrated that IFX and ETN have similar 
inhibitory effects on TLR 4 or TLR 2 expression in 
human synovial tissue [28]. However, there is no clear 
evidence about the altering effects of these drugs on 
TLR 2 and TLR 4 activities in mice. The drugs used in 
this study were previously administered for TNFα 
blockage in mouse models; it has been demonstrated 
that they lead to a decrease in TNFα levels in serum 
[29]. However, there is no clear information about the 
dosing of these drugs in mice; therefore, we 
administered the doses applied for humans. In addition 
to this, drug doses may influence the differences 
between the groups.   
Third, the histopathological evidence is critical. In 
the present study, extramedullary hematopoiesis was 
detected in spleen samples of mice infected with B. 
melitensis M16, and granuloma formation was 
detected in the majority (19/26; 73%) of them. It was 
previously reported that those two changes were the 
main signs in the spleen of the B. melitensis M16 
mouse model [30]. Our results revealed that there was 
granuloma formation in all liver samples, and 
extramedullary hematopoiesis was encountered in 
50% of the subjects. To date, we are not aware of a 
study investigating effects of TNFα neutralization on 
granuloma formation during Brucella infection. In one 
study, there was no significant difference in terms of 
granuloma formation between IL-10 knock-out mice 
in a B. abortus infection model and wild-type mice, 
even though higher TNFα levels were detected in the 
second week of infection [4]. The results of our study 
revealed that anti-TNFα drug use did not have any 
effect on granuloma formation either in the spleen or 
liver. This was also demonstrated in a M. tuberculosis 
mouse model [31]. 
In all anti-TNFα drug groups, there was neutrophil 
infiltration in the red pulp, but this difference reached 
statistical significance only in the ADA + B. melitensis 
group. In liver samples, apoptotic cells and hepatocyte 
pleomorphism were more prominent in the IFX + B. 
melitensis group. There are conflicting data about the 
hepatic effects of anti-TNFα drugs. In some patients, 
hepatotoxicity can develop due to IFX administration 
[32]. When the treatment was changed with ETN or 
ADA, hepatotoxicity disappeared in some patients 
who received IFX previously [33,34]. On the other 
hand, TNFα blockage was associated with the 
hepatoprotective effect in some conditions in mice 
models [35,36]. Another study reported that IFX 
treatment can control chronic hepatitis C infections by 
promoting apoptotic cells and preventing liver 
regeneration in a transgenic mouse model [37]. In our 
study, the detection of apoptotic cells and hepatocyte 
pleomorphism in the IFX + B. melitensis group, but 
not in the sham group, may indicate an altered 
response against Brucella infection.  
Using a mouse model to investigate the effects of 
anti-TNFα treatment in human brucellosis is the major 
limitation of our study; ethical restrictions make it 
impossible to conduct such a study on humans. Still, 
the critical role of TNFα on disease control is well 
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known for mouse brucellosis, allowing an argument 
from analogy with human brucellosis. It was shown in 
vitro that there was no TNFα production in human 
macrophages and dendritic cells after some Brucella 
spp. infections [38-40]. Some studies also reported 
that TNFα was absent or was not increased in human 
brucellosis [41,42]. In spite of these findings, 
Demirdag et al. reported that TNFα increased in 
human brucellosis and it was correlated with other 
inflammatory parameters such as C-reactive protein 
during the disease follow-up [5]. That study also 
showed that high TNFα levels were decreased by 
brucellosis treatment. A recently published study 
reported results similar to those of Demirdag et al. [6]. 
 
Conclusions 
Our results showed that anti-TNFα treatment was 
not associated with any difference in signs indicating 
disease severity, such as increased hepatic and splenic 
bacterial loads, granuloma formation, and 
extramedullary hematopoiesis in acute Brucella 
infection in mice. In order to safely use anti-TNFα 
drugs, we need to know whether there is a change in 
the prognosis or a reactivation of Brucella infection in 
the long term. Therefore, further studies are required 
to reveal the effects of anti-TNFα drugs on chronic 
Brucella infections and to follow the potential 
complications of anti-TNFα treatment, such as 
brucellosis reactivation, especially in endemic areas. 
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